Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Lee Philina

2. Date of Event Requiring Statement (MM/DD/YYYY) 4/4/2022

3. Issuer Name and Ticker or Trading Symbol

Blueprint Medicines Corp [BPMC]

(Last) (First) (Middle)

C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Commercial Officer /

(Street)

CAMBRIDGE, MA 02139

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	20354 ⁽¹⁾	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽²⁾	8/18/2024	Common Stock	261	$1.87	D
Stock Option (Right to Buy)	⁽²⁾	2/10/2025	Common Stock	523	$8.80	D
Stock Option (Right to Buy)	⁽²⁾	2/3/2026	Common Stock	1224	$15.01	D
Stock Option (Right to Buy)	⁽²⁾	2/16/2027	Common Stock	157	$36.05	D
Stock Option (Right to Buy)	⁽²⁾	7/3/2027	Common Stock	1042	$51.06	D
Stock Option (Right to Buy)	⁽²⁾	2/16/2028	Common Stock	5011	$81.44	D
Stock Option (Right to Buy)	⁽³⁾	3/1/2029	Common Stock	12350	$86.60	D
Stock Option (Right to Buy)	⁽⁴⁾	3/1/2030	Common Stock	8450	$54.13	D
Stock Option (Right to Buy)	⁽⁵⁾	3/1/2031	Common Stock	8650	$100.13	D
Stock Option (Right to Buy)	⁽⁶⁾	3/1/2032	Common Stock	17500	$61.31	D

Explanation of Responses:
(1)	The number reported includes restricted stock units previously granted to the Reporting Person.
(2)	This option is fully vested and exercisable as of the date hereof.
(3)	This option vests in forty-eight equal monthly installments, with the first installment vested on April 1, 2019.
(4)	This option vests in forty-eight equal monthly installments, with the first installment vested on April 1, 2020.
(5)	This option vests in forty-eight equal monthly installments, with the first installment vested on April 1, 2021.
(6)	This option vests in forty-eight equal monthly installments, with the first installment vested on April 1, 2022.

Remarks:
Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Lee Philina C/O BLUEPRINT MEDICINES CORPORATION 45 SIDNEY STREET CAMBRIDGE, MA 02139			Chief Commercial Officer

Signatures
/s/ Ariel Hurley, Attorney-in-Fact		4/14/2022
^**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.